Hub : Traits :

Qualifications: None of the above

726 significantly associated models · 136 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 43073464 45157738 12 3 2.0e-13 2.2e-15 3.1e-01 98 MED8 RP11-7O11.3 ST3GAL3
2 1 71163715 73435171 1 1 4.8e-10 4.2e-09 4.0e-04 64 NEGR1
3 1 92957826 94426916 3 1 1.4e-09 2.9e-07 8.8e-01 100 TMED5
4 1 109316076 110716511 1 1 6.3e-08 7.4e-07 4.5e-02 84 SYPL2
5 2 43899918 45698128 1 1 3.6e-09 8.4e-10 4.7e-02 90 CAMKMT
6 2 99922967 101731705 3 1 6.8e-09 6.5e-09 1.4e-01 93 CHST10
7 2 106725928 108199394 1 1 1.2e-07 1.9e-07 1.0e+00 100 ST6GAL2
8 3 16154636 17814553 1 1 2.2e-08 2.7e-09 1.8e-02 84 PLCL2
9 3 48268509 51009435 26 2 2.2e-15 2.1e-13 1.2e-01 96 GPX1 RBM6
10 3 52047421 53860103 3 1 1.7e-07 3.5e-08 8.0e-02 90 NEK4
11 3 107181540 108633112 1 1 1.0e-07 2.0e-06 1.4e-01 90 IFT57
12 3 124558741 125238099 1 1 1.9e-07 7.7e-08 1.4e-01 92 SLC12A8
13 4 2233366 3740612 2 1 2.7e-07 5.6e-08 3.7e-07 12 MFSD10
14 4 105598022 107092169 1 1 3.0e-09 3.2e-09 1.3e-02 82 PPA2
15 5 26181001 27729100 1 1 2.2e-07 6.9e-09 2.3e-04 60 CDH9
16 5 59193824 61156570 5 2 1.9e-17 3.2e-17 7.0e-01 100 ELOVL7
17 5 87006055 88875673 2 2 4.5e-10 7.9e-17 2.0e-08 55 CTC-498M16.2 MEF2C
18 5 176132977 177591495 3 1 5.9e-09 1.0e-08 1.0e+00 100 DBN1
19 6 87530372 88997402 1 1 2.8e-08 2.4e-08 1.0e+00 100 RARS2
20 7 23913624 25432157 1 1 3.5e-08 2.2e-08 1.0e+00 100 MPP6
21 8 30012514 31433801 1 1 1.8e-07 9.3e-08 1.0e-01 91 TEX15
22 8 142629143 144515639 2 3 2.2e-10 6.9e-11 4.9e-03 81 THEM6 TSNARE1
23 9 111008699 112472083 1 1 2.5e-07 2.2e-06 3.3e-02 80 CTNNAL1
24 10 10349662 12076043 1 1 1.6e-08 7.7e-08 1.0e-02 77 CELF2
25 10 64195778 65911294 4 1 3.4e-15 1.6e-15 1.1e-03 83 NRBF2
26 10 102853189 104242886 2 1 2.6e-08 1.0e-08 1.5e-03 69 NPM3
27 10 133048749 134482926 2 2 7.8e-10 2.2e-12 8.7e-01 100 BNIP3 PPP2R2D
28 11 94805896 96276010 4 1 1.9e-13 2.9e-13 2.2e-01 97 AP001877.1
29 11 116805204 117308936 1 1 6.5e-08 1.2e-04 6.5e-01 99 SIDT2
30 12 49556303 50927881 1 1 4.7e-08 4.9e-05 3.0e-02 71 BCDIN3D
31 12 55677395 57125879 5 1 5.4e-11 1.9e-10 1.0e+00 100 SUOX
32 12 122258047 124591385 13 2 1.4e-13 6.2e-12 6.6e-01 100 CDK2AP1 RSRC2
33 13 31078511 32595740 1 1 2.2e-07 1.7e-06 1.8e-01 92 B3GALTL
34 14 73853137 75366447 1 1 5.6e-08 3.0e-06 8.3e-04 49 LIN52
35 16 86671 1432491 1 1 1.4e-07 1.0e-06 7.4e-01 100 WDR24
36 16 24614505 25167985 1 1 1.5e-07 9.1e-09 1.6e-03 70 SLC5A11
37 16 27655848 29595483 19 1 3.6e-10 8.8e-10 5.3e-01 99 SULT1A1
38 16 52828325 54235440 2 1 2.5e-08 6.7e-09 8.6e-02 91 RBL2
39 17 34815551 35675511 1 1 1.5e-07 1.3e-06 5.4e-04 49 CTB-75G16.3
40 19 45064435 46506809 2 1 1.3e-11 1.5e-11 1.0e+00 100 CKM

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.87 2 0 0.0 0.00 1.0e+00 MPP6 NEK4
Bipolar Disorder or Schizophrenia 2.36 7 1 2.2 0.19 6.9e-01 CDK2AP1 ELOVL7 MED8 MPP6 NEK4 PLCL2 RP11-7O11.3
Depressed Affect (Nagel 2018) 3.30 5 2 4.4 0.70 1.9e-01 CDH9 CELF2 GPX1 PLCL2 RBM6
Depression (Nagel 2018) 2.61 2 0 0.0 0.00 1.0e+00 NRBF2 PLCL2
Intelligence (Savage-Jansen 2018) 8.44 29 16 35.6 -0.95 1.9e-16 AP001877.1 BNIP3 CAMKMT CDH9 CDK2AP1 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 PPP2R2D RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Neuroticism (Nagel 2018) 2.72 8 2 4.4 0.51 1.9e-01 B3GALTL CDH9 CELF2 CTC-498M16.2 GPX1 PLCL2 THEM6 TSNARE1
Schizophrenia (2018) 2.30 4 0 0.0 0.63 2.6e-01 CDK2AP1 ELOVL7 MED8 RP11-7O11.3
Worry (Nagel 2018) 2.45 5 2 4.4 0.63 2.6e-01 AP001877.1 B3GALTL CTC-498M16.2 PLCL2 TSNARE1
Crohns Disease (2017) 1.91 3 2 4.4 0.00 1.0e+00 GPX1 NEK4 SULT1A1
Irritable Bowel Disease (IBD) 2.26 3 2 4.4 0.00 1.0e+00 GPX1 RBM6 SULT1A1
Ulcerative Colitis (UC) 2.18 3 2 4.4 0.00 1.0e+00 GPX1 RBM6 SULT1A1
Major Depression (MDD) 2.83 2 1 2.2 0.00 1.0e+00 GPX1 NEGR1
Verbal and Numeric Reasoning (VNR) 7.64 22 11 24.4 -0.97 6.9e-14 CDH9 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Breast Cancer 1.24 1 0 0.0 0.00 1.0e+00 GPX1
Prostate Cancer 1.31 2 0 0.0 0.00 1.0e+00 GPX1 PPA2
Age at First Birth 3.89 3 2 4.4 0.00 1.0e+00 CHST10 GPX1 RBM6
Body Mass Index (BMI) (2010) 3.01 3 2 4.4 0.00 1.0e+00 CTB-75G16.3 NEGR1 SULT1A1
Crohns Disease (2012) 1.90 2 2 4.4 0.00 1.0e+00 GPX1 SULT1A1
HDL Cholesterol 1.61 2 1 2.2 0.00 1.0e+00 NRBF2 TMED5
LDL Cholesterol 1.53 1 0 0.0 0.00 1.0e+00 SIDT2
Primary Biliary Cirrhosis 1.22 1 0 0.0 0.00 1.0e+00 PLCL2
Schizophrenia (2014) 2.29 4 1 2.2 -0.30 7.0e-01 CDK2AP1 ELOVL7 PLCL2 TSNARE1
Triglycerides 3.21 2 2 4.4 0.00 1.0e+00 NRBF2 SIDT2
Ulcerative Colitis 1.91 2 1 2.2 0.00 1.0e+00 GPX1 RBM6
Blood Eosinophil Count 1.47 7 7 15.6 -0.17 7.2e-01 CDK2AP1 CKM NEK4 PLCL2 SIDT2 SUOX TMED5
Blood Platelet Count 3.53 8 6 13.3 -0.25 5.6e-01 CDK2AP1 CKM MEF2C MPP6 NRBF2 SIDT2 TMED5 WDR24
Blood Red Count 1.30 13 10 22.2 0.28 3.6e-01 AP001877.1 CAMKMT CHST10 CKM CTC-498M16.2 LIN52 MED8 MEF2C NRBF2 PLCL2 SULT1A1 SUOX TMED5
Blood White Count 1.84 12 9 20.0 0.64 2.4e-02 CKM CTC-498M16.2 GPX1 MED8 MFSD10 MPP6 NRBF2 PPA2 RBM6 SIDT2 SLC5A11 TEX15
Heel T-Score 0.86 4 2 4.4 0.72 2.8e-01 CDK2AP1 NEGR1 NEK4 SLC5A11
BMI 4.68 18 15 33.3 0.70 1.2e-03 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Height 1.85 20 14 31.1 -0.69 7.2e-04 AP001877.1 CAMKMT CDK2AP1 CTNNAL1 ELOVL7 GPX1 LIN52 MED8 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 TMED5 WDR24
Waist Hip Ratio (WHR) 2.08 8 4 8.9 0.36 3.8e-01 CDK2AP1 CTNNAL1 ELOVL7 GPX1 NEK4 PLCL2 RBL2 RSRC2
Systolic Blood Pressure 2.22 10 6 13.3 0.45 1.9e-01 GPX1 MED8 MPP6 NEK4 PPP2R2D RSRC2 SIDT2 SLC5A11 ST6GAL2 TSNARE1
Smoking Status 4.36 15 6 13.3 0.97 1.5e-09 CELF2 CKM ELOVL7 GPX1 IFT57 MED8 MEF2C MFSD10 NEK4 PLCL2 RBM6 RP11-7O11.3 SLC5A11 SUOX WDR24
Allergy or Eczema 2.69 7 3 6.7 -0.68 9.6e-02 CDK2AP1 CTB-75G16.3 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Cardiovascular Disease 2.39 6 2 4.4 -0.10 8.5e-01 MED8 NEGR1 RBL2 SIDT2 SULT1A1 TEX15
Hypothyroidism (self reported) 2.02 2 2 4.4 0.00 1.0e+00 SIDT2 SUOX
Respiratory disease 1.92 1 1 2.2 0.00 1.0e+00 SUOX
Type 2 Diabetes (T2D) (2018) 1.64 1 0 0.0 0.00 1.0e+00 RBL2
Lung FEV1/FVC ratio 1.67 7 4 8.9 0.12 8.0e-01 GPX1 LIN52 NEGR1 NRBF2 PPA2 SLC5A11 SUOX
Lung FVC 1.21 5 3 6.7 0.42 4.8e-01 BCDIN3D GPX1 MFSD10 NRBF2 SUOX
Neuroticism 2.54 6 2 4.4 0.61 1.9e-01 B3GALTL CTC-498M16.2 GPX1 PLCL2 SIDT2 TSNARE1
Chronotype (morning person) 2.23 4 0 0.0 0.63 3.7e-01 CAMKMT DBN1 LIN52 SYPL2
Hair Pigment 0.14 2 1 2.2 0.00 1.0e+00 CDK2AP1 SUOX
Hand grip strength (left) 1.40 3 2 4.4 0.00 1.0e+00 NEK4 NPM3 SLC5A11
Number of treatments/medications taken 3.12 6 2 4.4 0.75 8.8e-02 B3GALTL GPX1 NEGR1 PPP2R2D RBM6 ST6GAL2
Sensitivity / hurt feelings 1.61 1 0 0.0 0.00 1.0e+00 PLCL2
Frequency of depressed mood in last 2 weeks 2.03 2 0 0.0 0.00 1.0e+00 CELF2 PLCL2
Relative age of first facial hair 1.38 2 0 0.0 0.00 1.0e+00 MED8 NRBF2
Ever used hormone-replacement therapy (HRT) 1.60 1 0 0.0 0.00 1.0e+00 BCDIN3D
Systolic blood pressure, automated reading 2.78 7 4 8.9 0.65 1.1e-01 GPX1 MED8 MPP6 NEK4 PPA2 SLC5A11 TSNARE1
Supplements: Zinc 1.58 1 0 0.0 0.00 1.0e+00 NRBF2
Medication: Co-codamol 2.02 2 0 0.0 0.00 1.0e+00 GPX1 RBM6
Pack years adult smoking proportion 3.26 4 0 0.0 0.23 7.7e-01 BNIP3 GPX1 MFSD10 NRBF2
Impedance of leg (right) 2.29 11 5 11.1 -0.03 9.3e-01 AP001877.1 CTNNAL1 ELOVL7 GPX1 NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Leg fat-free mass (left) 2.76 16 10 22.2 0.04 8.7e-01 BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Trunk fat percentage 3.32 12 7 15.6 0.64 2.4e-02 CHST10 CTB-75G16.3 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Hand grip strength (right) 1.61 5 2 4.4 -0.14 8.3e-01 NEK4 NPM3 RBL2 SLC5A11 SULT1A1
Townsend deprivation index at recruitment 2.82 1 0 0.0 0.00 1.0e+00 CKM
Current tobacco smoking 3.59 1 0 0.0 0.00 1.0e+00 SLC5A11
Average weekly fortified wine intake 2.36 1 0 0.0 0.00 1.0e+00 SLC5A11
Maternal smoking around birth 3.69 4 1 2.2 -0.46 5.4e-01 CKM CTB-75G16.3 MED8 SLC5A11
Fed-up feelings 3.67 8 1 2.2 0.98 9.1e-06 B3GALTL CDK2AP1 GPX1 PLCL2 RBM6 SLC5A11 TEX15 THEM6
Frequency of unenthusiasm / disinterest in last 2 weeks 3.09 1 0 0.0 0.00 1.0e+00 GPX1
Taking other prescription medications 2.75 3 1 2.2 0.00 1.0e+00 B3GALTL GPX1 RBM6
Age when periods started (menarche) 2.66 7 5 11.1 0.65 1.1e-01 CTNNAL1 GPX1 MED8 NEGR1 NRBF2 RP11-7O11.3 SUOX
Qualifications: CSEs or equivalent 2.58 2 0 0.0 0.00 1.0e+00 GPX1 ST3GAL3
High blood pressure 2.53 8 0 0.0 0.56 1.5e-01 NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Hayfever, allergic rhinitis or eczema 2.60 6 1 2.2 -0.66 1.6e-01 CDK2AP1 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Medication: Levothyroxine sodium 1.45 1 1 2.2 0.00 1.0e+00 SUOX
Sitting height 1.99 9 6 13.3 -0.97 2.1e-05 CAMKMT CDK2AP1 MED8 NEK4 PPA2 PPP2R2D RBL2 RSRC2 WDR24
Body mass index (BMI) 4.76 19 11 24.4 0.76 1.5e-04 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 MPP6 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Impedance of leg (left) 2.35 12 7 15.6 0.00 9.9e-01 AP001877.1 CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Leg predicted mass (left) 2.77 16 10 22.2 0.04 8.7e-01 BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Trunk fat mass 3.47 11 9 20.0 0.57 7.0e-02 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Waist circumference 3.94 15 8 17.8 0.72 2.6e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Past tobacco smoking 2.63 4 0 0.0 -1.00 4.6e-03 CELF2 RP11-7O11.3 SUOX WDR24
Alcohol usually taken with meals 5.07 5 1 2.2 -0.98 8.6e-04 CHST10 ELOVL7 MED8 NEGR1 NRBF2
Nervous feelings 2.23 3 0 0.0 0.00 1.0e+00 B3GALTL CTC-498M16.2 TSNARE1
Frequency of tenseness / restlessness in last 2 weeks 2.14 2 2 4.4 0.00 1.0e+00 B3GALTL GPX1
Had other major operations 1.50 1 0 0.0 0.00 1.0e+00 PPA2
Forced vital capacity (FVC) 1.75 8 2 4.4 -0.99 4.4e-07 BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBL2 RBM6 RSRC2
Mouth/teeth dental problems 2.28 1 0 0.0 0.00 1.0e+00 ELOVL7
Allergy 2.29 3 2 4.4 0.00 1.0e+00 CDK2AP1 NEGR1 SUOX
Pain all over the body in last month 2.58 1 0 0.0 0.00 1.0e+00 GPX1
Diabetes (self-reported) 1.87 2 0 0.0 0.00 1.0e+00 RBL2 ST6GAL2
Hayfever/allergic rhinitis (self-reported) 1.55 1 0 0.0 0.00 1.0e+00 SUOX
Medication: Simvastatin 1.71 1 0 0.0 0.00 1.0e+00 SIDT2
Fluid intelligence score 8.15 26 11 24.4 -0.98 4.1e-19 BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Illnesses of siblings 2.72 3 1 2.2 0.00 1.0e+00 RBL2 SLC5A11 ST3GAL3
Neuroticism score 2.41 4 2 4.4 0.99 1.3e-02 B3GALTL CELF2 GPX1 PLCL2
Weight 3.54 14 10 22.2 0.44 1.1e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Impedance of arm (right) 3.07 10 8 17.8 -0.47 1.4e-01 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX SYPL2
Arm fat percentage (right) 3.92 14 8 17.8 0.68 7.7e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Trunk fat-free mass 2.43 14 9 20.0 -0.10 7.3e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Hip circumference 3.24 12 8 17.8 0.27 4.0e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Alcohol intake versus 10 years previously 3.48 3 0 0.0 0.00 1.0e+00 GPX1 NEGR1 RP11-7O11.3
Father's age at death 2.32 2 0 0.0 0.00 1.0e+00 CDK2AP1 GPX1
Worrier / anxious feelings 2.44 4 1 2.2 0.65 3.5e-01 AP001877.1 B3GALTL NEK4 PLCL2
Frequency of tiredness / lethargy in last 2 weeks 2.35 1 0 0.0 0.00 1.0e+00 GPX1
Number of live births 1.76 1 0 0.0 0.00 1.0e+00 RBM6
Forced expiratory volume in 1-second (FEV1) 2.12 7 2 4.4 -0.70 8.2e-02 BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBM6 SUOX
Pulse rate 1.21 1 0 0.0 0.00 1.0e+00 RBL2
Qualifications: A levels/AS levels or equivalent 10.38 30 16 35.6 -0.99 1.0e-24 AP001877.1 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM DBN1 ELOVL7 GPX1 IFT57 MED8 MPP6 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX THEM6 TMED5 TSNARE1 WDR24
Mouth/teeth dental problems: Dentures 3.75 4 1 2.2 0.99 9.5e-03 BCDIN3D GPX1 RBM6 TMED5
Asthma 1.73 1 1 2.2 0.00 1.0e+00 SUOX
Medication: Cholesterol lowering 1.49 1 0 0.0 0.00 1.0e+00 SIDT2
Prospective memory result 2.70 1 0 0.0 0.00 1.0e+00 PLCL2
Illnesses of mother 1.75 1 0 0.0 0.00 1.0e+00 CTB-75G16.3
Forced expiratory volume in 1-second (FEV1), Best measure 2.17 6 3 6.7 -0.55 2.6e-01 GPX1 MFSD10 PLCL2 PPA2 RBM6 SUOX
Impedance of arm (left) 3.08 10 7 15.6 -0.74 1.5e-02 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX
Arm fat mass (right) 4.25 14 9 20.0 0.67 9.2e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Trunk predicted mass 2.43 14 9 20.0 -0.10 7.1e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Standing height 2.08 16 11 24.4 -0.84 4.7e-05 CAMKMT CDK2AP1 GPX1 MED8 MFSD10 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 WDR24
Exposure to tobacco smoke at home 2.21 1 0 0.0 0.00 1.0e+00 GPX1
Breastfed as a baby 2.23 1 0 0.0 0.00 1.0e+00 CDK2AP1
Seen doctor (GP) for nerves, anxiety, tension or depression 2.32 2 1 2.2 0.00 1.0e+00 B3GALTL NEGR1
Birth weight of first child 2.17 2 1 2.2 0.00 1.0e+00 PPA2 SUOX
Ever highly irritable/argumentative for 2 days 2.40 2 1 2.2 0.00 1.0e+00 GPX1 RBM6
Qualifications: O levels/GCSEs or equivalent 7.86 18 3 6.7 -0.98 8.3e-13 AP001877.1 CAMKMT CDK2AP1 CKM CTB-75G16.3 ELOVL7 GPX1 IFT57 MFSD10 MPP6 NRBF2 PLCL2 PPP2R2D RP11-7O11.3 ST3GAL3 ST6GAL2 THEM6 TSNARE1
Medication: Paracetamol 2.13 2 0 0.0 0.00 1.0e+00 GPX1 TMED5
Headache pain in last month 1.30 1 0 0.0 0.00 1.0e+00 SUOX
Hypothyroidism/myxoedema (self-reported) 1.86 2 1 2.2 0.00 1.0e+00 SIDT2 SUOX
Medication: Ventolin 100micrograms inhaler 1.49 1 0 0.0 0.00 1.0e+00 SUOX
Birth weight 1.69 1 0 0.0 0.00 1.0e+00 PPA2
High blood pressure (siblings) 2.37 1 0 0.0 0.00 1.0e+00 SLC5A11
Forced vital capacity (FVC), Best measure 1.83 8 2 4.4 -0.65 8.2e-02 BCDIN3D GPX1 MFSD10 PPA2 RBL2 RBM6 RSRC2 SUOX
Body fat percentage 4.02 15 9 20.0 0.69 4.1e-03 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6
Leg fat percentage (right) 5.28 20 10 22.2 0.78 5.6e-05 BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Arm fat-free mass (right) 2.68 13 11 24.4 0.09 7.7e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Exposure to tobacco smoke outside home 3.00 2 0 0.0 0.00 1.0e+00 ELOVL7 RBM6
Comparative body size at age 10 3.14 7 4 8.9 0.03 9.5e-01 BCDIN3D CTB-75G16.3 CTC-498M16.2 MEF2C NEGR1 RBM6 SULT1A1
Number of full brothers 1.91 2 0 0.0 0.00 1.0e+00 GPX1 RBM6
Worry too long after embarrassment 2.20 3 0 0.0 0.00 1.0e+00 BCDIN3D DBN1 THEM6
Wheeze or whistling in the chest in last year 2.52 2 1 2.2 0.00 1.0e+00 GPX1 RBM6
Reason for reducing amount of alcohol drunk: Health precaution 2.05 2 0 0.0 0.00 1.0e+00 CTC-498M16.2 SUOX
Age at first live birth 5.79 7 2 4.4 -0.96 5.0e-04 AP001877.1 GPX1 NRBF2 RBM6 RP11-7O11.3 SUOX WDR24
Health satisfaction 2.03 3 0 0.0 0.00 1.0e+00 GPX1 MFSD10 TSNARE1
Qualifications: College or University degree 12.87 39 32 71.1 -0.98 7.4e-29 AP001877.1 B3GALTL BCDIN3D BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 CTC-498M16.2 DBN1 ELOVL7 GPX1 IFT57 MED8 MFSD10 MPP6 NEGR1 NPM3 NRBF2 PPA2 PPP2R2D RARS2 RBL2 RBM6 RP11-7O11.3 RSRC2 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 THEM6 TMED5 TSNARE1 WDR24
Medication for pain relief, constipation, heartburn 2.45 4 1 2.2 -0.34 6.6e-01 CDK2AP1 GPX1 ST6GAL2 TEX15
Neck or shoulder pain in last month 1.64 2 0 0.0 0.00 1.0e+00 GPX1 SUOX
Medication: Blood pressure 1.94 1 0 0.0 0.00 1.0e+00 NEK4
Mean time to correctly identify matches 1.56 1 0 0.0 0.00 1.0e+00 IFT57
Whole body fat mass 4.06 14 9 20.0 0.65 1.1e-02 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Leg fat mass (right) 4.85 16 10 22.2 0.71 2.1e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Arm predicted mass (right) 2.69 13 11 24.4 0.11 7.0e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Pulse rate, automated reading 1.69 4 2 4.4 0.58 4.2e-01 CTC-498M16.2 NEGR1 RBL2 SLC5A11
Alcohol intake frequency. 4.16 10 3 6.7 0.80 6.0e-03 B3GALTL BNIP3 CDK2AP1 CTC-498M16.2 NEGR1 RBM6 SULT1A1 TEX15 TSNARE1 WDR24
Comparative height size at age 10 2.13 12 9 20.0 -0.73 7.1e-03 BCDIN3D CAMKMT CDK2AP1 MED8 NEK4 RBL2 RBM6 RP11-7O11.3 RSRC2 SULT1A1 TMED5 WDR24
Suffer from 'nerves' 1.95 3 0 0.0 0.00 1.0e+00 B3GALTL CTC-498M16.2 SULT1A1
Overall health rating 5.53 12 7 15.6 0.97 1.2e-07 B3GALTL CKM GPX1 MFSD10 NRBF2 PPP2R2D RBL2 RBM6 SLC5A11 TEX15 THEM6 TSNARE1
Age at last live birth 4.35 3 2 4.4 0.00 1.0e+00 AP001877.1 GPX1 RBM6
Leg pain on walking 1.72 1 0 0.0 0.00 1.0e+00 GPX1
Commuting to job workplace: Car/motor vehicle 1.60 1 0 0.0 0.00 1.0e+00 NEGR1
Hypertension (Self-reported) 2.58 7 1 2.2 0.62 1.4e-01 NEGR1 NRBF2 RBL2 SLC5A11 SUOX TEX15 TSNARE1
Whole body fat-free mass 2.58 14 11 24.4 -0.06 8.4e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Leg fat-free mass (right) 2.68 16 10 22.2 -0.14 5.9e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Arm fat percentage (left) 3.80 15 7 15.6 0.68 5.7e-03 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Average weekly red wine intake 5.10 7 2 4.4 -0.98 7.1e-05 AP001877.1 CAMKMT CDK2AP1 CTC-498M16.2 NRBF2 RBM6 RP11-7O11.3
Handedness (chirality/laterality): Left-handed 1.46 1 0 0.0 0.00 1.0e+00 SULT1A1
Mood swings 2.87 5 1 2.2 0.99 1.1e-03 CELF2 GPX1 PLCL2 RBM6 SLC5A11
Loneliness, isolation 2.03 1 0 0.0 0.00 1.0e+00 GPX1
Long-standing illness, disability or infirmity 1.80 1 0 0.0 0.00 1.0e+00 NEGR1
Diabetes diagnosed by doctor 1.70 1 0 0.0 0.00 1.0e+00 RBL2
Friendships satisfaction 1.84 1 0 0.0 0.00 1.0e+00 AP001877.1
Qualifications: nursing, teaching 7.18 9 3 6.7 -0.99 1.3e-07 B3GALTL CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RP11-7O11.3 ST3GAL3
Mouth/teeth dental problems: Mouth ulcers 1.51 1 0 0.0 0.00 1.0e+00 AP001877.1
Medication for cholesterol 1.90 1 0 0.0 0.00 1.0e+00 RBL2
Mineral and other dietary supplements 2.22 1 0 0.0 0.00 1.0e+00 CTC-498M16.2
Asthma (self-reported) 1.76 2 1 2.2 0.00 1.0e+00 CDK2AP1 SUOX
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.71 1 0 0.0 0.00 1.0e+00 PPA2
Whole body water mass 2.60 14 11 24.4 -0.06 8.4e-01 CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Leg predicted mass (right) 2.66 15 10 22.2 -0.16 5.6e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Arm fat mass (left) 4.13 14 9 20.0 0.67 9.0e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Number of self-reported non-cancer illnesses 1.99 1 1 2.2 0.00 1.0e+00 NEGR1
Average weekly champagne plus white wine intake 3.63 2 0 0.0 0.00 1.0e+00 SULT1A1 WDR24
Miserableness 3.38 4 3 6.7 1.00 3.9e-03 B3GALTL CELF2 GPX1 RBM6
Guilty feelings 1.89 1 0 0.0 0.00 1.0e+00 GPX1
Financial situation satisfaction 2.23 1 1 2.2 0.00 1.0e+00 GPX1
Commuting to job workplace: Public transport 2.83 2 0 0.0 0.00 1.0e+00 CHST10 NEGR1
High cholesterol (Self-reported) 1.67 1 1 2.2 0.00 1.0e+00 SIDT2
Medication: Bendroflumethiazide 1.82 1 1 2.2 0.00 1.0e+00 TEX15
Medication: Paracetamol 2.05 2 0 0.0 0.00 1.0e+00 GPX1 TMED5
Medication: Atorvastatin 1.59 1 0 0.0 0.00 1.0e+00 SIDT2
Ever smoked 2.44 2 0 0.0 0.00 1.0e+00 CDK2AP1 WDR24
Basal metabolic rate 2.81 15 11 24.4 0.11 6.8e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Leg fat percentage (left) 5.30 20 11 24.4 0.78 5.6e-05 BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Arm fat-free mass (left) 2.85 14 11 24.4 0.14 6.2e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Number of operations (self-reported) 2.11 2 0 0.0 0.00 1.0e+00 PPA2 RBM6
Average weekly beer plus cider intake 3.04 2 0 0.0 0.00 1.0e+00 NRBF2 RBM6
Ever had prostate specific antigen (PSA) test 1.67 1 0 0.0 0.00 1.0e+00 CTC-498M16.2
Age started oral contraceptive pill 2.06 2 0 0.0 0.00 1.0e+00 GPX1 IFT57
Diastolic blood pressure, automated reading 2.81 9 5 11.1 0.70 3.5e-02 CDK2AP1 GPX1 MED8 MPP6 NRBF2 SLC5A11 ST6GAL2 THEM6 TSNARE1
Unable to work because of sickness or disability 3.20 2 0 0.0 0.00 1.0e+00 ELOVL7 SLC5A11
Vascular/heart problems diagnosed by doctor 2.68 9 1 2.2 -0.47 2.0e-01 MED8 NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Cholesterol lowering medication 2.10 1 0 0.0 0.00 1.0e+00 SIDT2
Pain experienced in last month 2.88 3 1 2.2 0.00 1.0e+00 GPX1 RBM6 SUOX
Pack years of smoking 2.93 2 0 0.0 0.00 1.0e+00 GPX1 MFSD10
Impedance of whole body 2.83 13 9 20.0 -0.41 1.5e-01 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 NEK4 NRBF2 PPA2 RBM6 SUOX SYPL2
Leg fat mass (left) 4.88 16 10 22.2 0.71 2.1e-03 CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Arm predicted mass (left) 2.89 14 12 26.7 0.15 6.0e-01 CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 17 0.49 2.2
GTEx Adipose Visceral Omentum 11 0.54 2.3
GTEx Adrenal Gland 4 0.27 2.0
GTEx Artery Aorta 17 0.57 2.2
GTEx Artery Coronary 2 0.17 2.2
GTEx Artery Tibial 26 0.69 2.2
GTEx Brain Caudate basal ganglia 5 0.54 2.2
GTEx Brain Cerebellar Hemisphere 9 0.60 2.4
GTEx Brain Cerebellum 10 0.50 2.3
GTEx Brain Cortex 7 0.68 2.2
GTEx Brain Frontal Cortex BA9 5 0.54 2.3
GTEx Brain Hippocampus 2 0.38 2.2
GTEx Brain Hypothalamus 1 0.17 2.0
GTEx Brain Nucleus accumbens basal ganglia 3 0.35 2.3
GTEx Brain Putamen basal ganglia 3 0.48 2.2
GTEx Breast Mammary Tissue 13 0.66 2.3
GTEx Breast Mammary Tissue (Male) 3 0.25 2.1
GTEx Breast Mammary Tissue (Female) 12 0.73 2.3
GTEx Cells EBV-transformed lymphocytes 5 0.35 2.2
GTEx Cells Transformed fibroblasts 24 0.57 2.2
GTEx Colon Sigmoid 9 0.62 2.4
GTEx Colon Transverse 12 0.58 2.2
GTEx Esophagus Gastroesophageal Junction 7 0.48 2.3
GTEx Esophagus Mucosa 19 0.57 2.2
GTEx Esophagus Muscularis 22 0.68 2.3
GTEx Heart Atrial Appendage 9 0.57 2.3
GTEx Heart Left Ventricle 8 0.52 2.2
GTEx Liver 3 0.42 2.2
GTEx Lung 15 0.52 2.2
GTEx Muscle Skeletal 18 0.62 2.3
GTEx Nerve Tibial 24 0.56 2.2
GTEx Ovary 5 0.55 2.3
GTEx Pancreas 14 0.86 2.3
GTEx Pituitary 4 0.36 2.2
GTEx Prostate 5 0.60 2.2
GTEx Skin Not Sun Exposed Suprapubic 16 0.65 2.3
GTEx Skin Sun Exposed Lower leg 18 0.49 2.2
GTEx Small Intestine Terminal Ileum 4 0.87 2.2
GTEx Spleen 7 0.50 2.3
GTEx Stomach 12 0.83 2.4
GTEx Testis 14 0.44 2.3
GTEx Thyroid 19 0.48 2.2
GTEx Uterus 1 0.18 2.1
GTEx Vagina 5 0.79 2.2
GTEx Whole Blood 6 0.30 2.1
METSIM Adipose 17 0.37 2.1
NTR Blood 5 0.21 2.0
ROSMAP Brain Pre-frontal Cortex 19 0.43 2.2
YFS Blood 14 0.30 2.0
CommonMind Brain Pre-frontal Cortex 16 0.30 2.1
The Cancer Genome Atlas Bladder Urothelial Carcinoma 7 0.42 2.1
The Cancer Genome Atlas Breast Invasive Carcinoma 14 0.32 2.0
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 5 0.46 2.1
The Cancer Genome Atlas Colon Adenocarcinoma 8 0.39 2.0
The Cancer Genome Atlas Esophageal Carcinoma 1 0.15 1.9
The Cancer Genome Atlas Glioblastoma Multiforme 5 0.49 2.2
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 12 0.44 2.1
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 14 0.34 2.0
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 8 0.39 2.1
The Cancer Genome Atlas Brain Lower Grade Glioma 16 0.37 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 8 0.72 2.1
The Cancer Genome Atlas Lung Adenocarcinoma 14 0.48 2.1
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 10 0.40 2.0
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 6 0.38 2.0
The Cancer Genome Atlas Pancreatic Adenocarcinoma 11 0.66 2.1
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 7 0.53 2.1
The Cancer Genome Atlas Prostate Adenocarcinoma 19 0.41 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.29 2.1
The Cancer Genome Atlas Soft Tissue Sarcoma 2 0.19 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 2 0.37 2.0
The Cancer Genome Atlas Stomach Adenocarcinoma 6 0.36 2.1
The Cancer Genome Atlas Testicular Germ Cell Tumors 4 0.31 2.0
The Cancer Genome Atlas Thyroid Carcinoma 17 0.33 2.0
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.39 2.0